MORRISTOWN, NJ – Over the last two decades, exceptional advancements have been made in cancer research and treatment. From improved technology that more accurately diagnoses a patient to innovative treatments such as immunotherapy, there is more hope for the estimated 1.5 million Americans who are diagnosed with some form of cancer every year, according to statistics from the Center for Disease Control.
Despite the progressive developments in cancer care and research, there is still much work to be done in the field to improve the outlook of patients’ lives through more effective treatments and earlier ways to detect cancerous cells. While it is now known that specific genotypes are more susceptible to aggressive forms to cancer, there are still mysteries as to why some stubbornly don’t react as well as others to treatment.
That’s where leading hematologists and oncologists Dr. Charles Farber and Dr. Michael Scola, the latest doctors to join Atlantic Health System come in. The physicians, who are both long-time members of the Morristown Medical Center cancer care community bring decades of experience and an interminable passion to the industry.
In addition to the consummate experience that Drs. Farber and Scola bring to Atlantic Health System are the anticipation of new initiatives that expect to pace the industry on the brink of the next great cancer breakthrough.
“Both Drs. Farber and Dr. Scola are outstanding clinicians as well as leaders in their subspecialties,” said Eric D. Whitman, MD, medical director, Atlantic Health System Cancer Care. “They are ideal candidates to lead these new initiatives, which will provide highly specialized care to our patients as well as increased access to breakthrough treatments and clinical trials.”
Dr. Scola is an internist with fellowship training in hematology/oncology. For the past decades, he has maintained a broad-based clinical practice, with a focus on benign and malignant hematology. His postdoctoral training includes a fellowship in hematology and medical oncology at Boston University Medical Center, where he received the Outstanding Fellow award and received the Chiefs’ Hematology Award for clinical excellence.
“The opportunity to start the Atlantic Thrombosis Center is the culmination of my longstanding interests in blood clotting and its complications,” said Dr. Scola. “There is a great need to provide leading edge care for patients with clotting disorders, and this new center will enable us to dedicate time and resources to providing optimal treatment.”
Meanwhile, Dr. Farber will continue as a general oncologist with a concentration in malignant hematology. He will also serve as the medical director of Oncology Research Network Development for Atlantic Health System, which features the recently added Breakthrough Oncology Accelerator (BOA) as a key component of the program as previously covered by TAP into Morristown.
The BOA flagship platform at Atlantic Health System is based on a partnership with Translational Genomics Research Institute (TGen) and OriginCV to provide better access to cancer treatment while improving patient outcomes through the integration of clinicians and researchers. Both of which are critical to the evolution of cancer care.
That is the motivating factor of why Dr. Farber and Dr. Scola are developing a Hematology and Medical Oncology fellowship training program that expects to have six trainees as they plan to integrate the latest technology to through clinical trials in an effort to identify that next breakthrough in cancer care. The fellowship training program is expected to launch in July 2020.
“I’m looking forward to co-leading the upcoming program with Dr. Scola as we transform the way that cancer care is delivered not just in our region but across the world,” explained Dr. Farber. “It is an exciting time to develop new models of cancer care.”
The new offices of Dr. Farber and Dr. Scola are located on the 2nd floor of the Carol G. Simon Cancer Center at Morristown Medical Center, 100 Madison Avenue. For more information, call 973-971-7960.